5 Key Takeaways

• 1

  The DME AWARE Study identified key unmet needs in diabetic macular edema management, emphasizing early intervention and noninvasive therapies.

• 2

  Approximately 60% of patients with diabetic macular edema remain untreated a year after diagnosis, highlighting significant treatment gaps.

• 3

  Panelists favored noninvasive treatments over intravitreal therapy, especially for patients with mild or early-stage diabetic macular edema.

• 4

  Consensus was reached on defining poor treatment response as less than a 10% reduction in central subfield thickness in diabetic macular edema.

• 5

  The study revealed limitations of existing therapies, with 25-40% of patients not achieving optimal outcomes even with anti-VEGF agents.